XVIVO is the only MedTech company dedicated to extending the life of all major organs—lungs, hearts, livers, and kidneys. Far too many people do not receive the lifesaving transplants they desperately need. XVIVO is determined to change this and realize its vision that “nobody should die waiting for a new organ.” This is a huge challenge, but XVIVO addresses it alongside dedicated and highly skilled transplant teams worldwide. These teams could save more lives if they had access to more organs. Thanks to XVIVO’s innovative technologies for transporting, preserving, and assessing organs outside the body, this will be possible.
Approximately 160,000 organ transplants are performed annually, but according to the World Health Organization (WHO), this only meets 10% of the global need. Many patients die while on the waiting list. For the last 50 years, organ preservation has relied on ice storage, but this method has limitations. For example, a heart can remain outside the body for only 3 to 4 hours when placed in a traditional ice box before it starts to deteriorate. This may seem like a long time, but it isn’t. The limited time is one of the main reasons that only 3 out of 10 available hearts are transplanted. The XVIVO Heart Assist Transport device preserves hearts at 8 degrees Celsius (46.4 degrees Fahrenheit) while circulating a tailored oxygenated solution, keeping them in good condition for up to 8 hours. This has been shown to reduce post-transplant risk factors, allowing hearts to travel longer distances and giving transplant teams crucial additional time.
XVIVO is also breaking new ground in the US with its heart technology, which is currently undergoing a clinical trial at 15 major transplant clinics. The heart technology is not yet FDA approved and the results of this trial will be used in the application process to the FDA seeking approval. Meanwhile, in Europe, a recent trial published in The Lancet demonstrated that XVIVO’s heart technology reduced the risk of early donor heart dysfunction by 61%, a significant breakthrough in the field.
Beyond improving patient outcomes, XVIVO’s technologies offer socio-economic and environmental benefits. In an ongoing European trial, hearts are being transported in XVIVO’s perfusion device in economy class aboard commercial airliners, unlike the conventional practice of using expensive private jets. This is a first in the field. Recognizing the financial strain on the American healthcare system, XVIVO understands the urgency to explore all alternatives. This innovation has the potential to substantially reduce both costs and carbon emissions.
Another key advantage of XVIVO’s technologies is their potential to improve the work-life balance of transplant teams. A recent liver preservation trial demonstrated that surgeries can be scheduled during daytime hours, reducing the need for night-time procedures, which also leads to better patient outcomes. XVIVO’s heart technology is expected to offer similar benefits, helping ease the pressure on overworked surgical teams.
With a strong commitment to innovation, sustainability, and patient outcomes, XVIVO is poised to transform organ transplantation, offering hope to thousands of patients and their families worldwide.
